Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study.
Fiche publication
Date publication
avril 2024
Journal
The Lancet. Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BEN ABDELGHANI Meher, Pr BORG Christophe, Pr BOUCHE Olivier, Pr GHIRINGHELLI François, Dr VERNEREY Dewi, Dr KIM Stephano, Pr BIBEAU Frédéric
Tous les auteurs :
Kim S, Ghiringhelli F, de la Fouchardière C, Evesque L, Smith D, Badet N, Samalin E, Lopez-Trabada Ataz D, Parzy A, Desramé J, Baba Hamed N, Buecher B, Tougeron D, Bouché O, Dahan L, Chibaudel B, El Hajbi F, Mineur L, Dubreuil O, Ben Abdelghani M, Pecout S, Bibeau F, Herfs M, Garcia ML, Meurisse A, Vernerey D, Taïeb J, Borg C
Lien Pubmed
Résumé
The modified docetaxel, cisplatin, and fluorouracil (mDCF) regimen has shown efficacy and safety as first-line treatment for advanced squamous cell carcinoma of the anus, making it a standard regimen. Inhibitors of programmed cell death protein 1 and its ligand, such as pembrolizumab, nivolumab, retifanlimab, avelumab, and atezolizumab, have shown some antitumour activity as monotherapy in advanced squamous cell carcinoma of the anus that is refractory to chemotherapy. This phase 2 study evaluated the combination of mDCF and atezolizumab as first-line treatment in advanced squamous cell carcinoma of the anus.
Mots clés
Humans, Female, Middle Aged, Aged, Male, Docetaxel, Cisplatin, adverse effects, Fluorouracil, adverse effects, B7-H1 Antigen, Neoplasm Recurrence, Local, drug therapy, Carcinoma, Squamous Cell, Anus Neoplasms, drug therapy, Antineoplastic Combined Chemotherapy Protocols, adverse effects, Antibodies, Monoclonal, Humanized
Référence
Lancet Oncol. 2024 04;25(4):518-528